Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) to Ring The Nasdaq Stock Market Closing Bell
October 03 2016 - 3:19PM
What:Paratek Pharmaceuticals,
Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the
development and commercialization of innovative therapies based
upon its expertise in novel tetracycline chemistry, will visit the
Nasdaq MarketSite in Times Square.
In honor of the occasion, Michael Bigham, Chairman and
Chief Executive Officer, will ring the Closing
Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Tuesday, October 4, 2016 – 3:45 p.m. to
4:00 p.m. ET
Paratek Contact:Michael
Lampe(484) 575-5040michael@scientpr.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About ParatekParatek Pharmaceuticals,
Inc. is a biopharmaceutical company focused on the development
and commercialization of innovative therapies based upon its
expertise in novel tetracycline chemistry. Paratek's lead product
candidate, omadacycline, is the first in a new class of
tetracyclines known as aminomethylcyclines, with broad-spectrum
activity against Gram-positive, Gram-negative and atypical
bacteria. In June 2016 Paratek announced positive
efficacy data in a Phase 3 registration study in ABSSSI
demonstrating the efficacy and safety of omadacycline compared to
linezolid. A Phase 3 registration study for community acquired
bacterial pneumonia (CABP) comparing IV to oral omadacycline to IV
to oral moxifloxacin was initiated in November 2015.
Enrollment continues on track to report top line data, which are
expected as early as the third quarter of 2017. A Phase 3
registration study in ABSSSI comparing once-daily oral only dosing
of omadacycline to twice-daily oral-only dosing of linezolid was
initiated in August 2016. Top line data are expected as early
as the second quarter of 2017. A phase 1b study in uncomplicated
urinary tract infections (UTI) was initiated in May 2016.
Enrollment is nearly complete with top line data expected as early
as the fourth quarter of 2016. Omadacycline has been granted
Qualified Infectious Disease Product designation and Fast Track
status by the U.S. Food and Drug Administration.
Omadacycline is a new once-daily oral and IV, well-tolerated
broad spectrum antibiotic being developed for use as empiric
monotherapy for patients suffering from serious community-acquired
bacterial infections, such as acute bacterial skin and skin
structure infections, community acquired bacterial pneumonia,
urinary tract infections and other community-acquired bacterial
infections, particularly when antibiotic resistance is of concern
to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is
designed to be a well-tolerated, once-daily, oral, narrow spectrum
tetracycline-derived antibiotic with potent anti-inflammatory
properties for the potential treatment of acne and rosacea in the
community setting. Allergan owns the U.S. rights for the
development and commercialization of sarecycline. Paratek retains
all ex-U.S. rights. Allergan initiated two identical
Phase 3 registration studies in December 2014 for
sarecycline for the treatment of moderate to severe acne vulgaris.
Top line data are expected in the first half of 2017. For more
information, visit www.paratekpharma.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first electronic
stock market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.3 trillion and nearly 18,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024